NCT02992392 is a NA clinical trial of Liposic in Dry Eye, sponsored by Sun Yat-sen University.

Who is sponsoring NCT02992392?

NCT02992392 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT02992392?

Interventions in NCT02992392: Liposic, Tears Naturale Forte.

Is NCT02992392 still recruiting?

NCT02992392 is currently status unknown. Last updated 14 December 2016.

Last reviewed 2016-12-14 · How we verify

NCT02992392

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome

Status unknown NA Last updated 14 December 2016

What this trial tests

NA trial testing Liposic in Dry Eye in 50 participants. Status unknown.

Timeline

1 December 2016

Primary endpoint
1 May 2017

1 June 2017

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	1 December 2016
Primary completion	1 May 2017
Estimated completion	1 June 2017
Sites	1 location across China

Drugs / interventions tested

Liposic — full drug profile →
Tears Naturale Forte — full drug profile →

Conditions studied

Dry Eye — all drugs for Dry Eye →

Sponsor

Sun Yat-sen University

Who can join

Adults 20 to 40, any sex, with Dry Eye. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

scale of Schirmer I test
Time frame: up to 3 months after tear substitutes apply
scale of corneal fluorescein staining
Time frame: up to 3 months after tear substitutes apply
scale of noninvasive tear breakup time
Time frame: up to 3 months after tear substitutes apply
scale of tear meniscus height
Time frame: up to 3 months after tear substitutes apply
lipid layer grade
Time frame: up to 3 months after tear substitutes apply
questionnaire of ocular surface disease index
Time frame: up to 3 months after tear substitutes apply

Sponsor's own description

With the potential to address evaporative dry eye, Liposic and Tears Naturale Forte have been developed in which phospholipid liposomes are delivered to the tear film via the surface of the closed eyelid. This study compare the effects of Liposic and Tears Naturale Forte application on the lipid and stability of the tear film in dry eye patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases.
Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, et al · · 2018 · cited 231× · PMID 29495528 · DOI 10.3390/pharmaceutics10010028
Recent advances and future challenges in nanosystems for ocular drug delivery.
Shahror RA, Fouda AY. · · 2025 · cited 1× · PMID 41478665 · DOI 10.1016/j.jpet.2025.103738

Verify or expand the search:

Other trials of Liposic

Trials testing the same drug.

NCT03211351 — Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome · NA · completed

Other recruiting trials for Dry Eye

Currently open trials in the same condition.

NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
NCT07329712 — Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy · recruiting
NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
NCT07298811 — Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment · Phase 1, PHASE2 · recruiting
NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02992392 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 14 December 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02992392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing